Table 2. Characterization of LPS Plasma... | American Society of Hematology

Table 2.

Characterization of LPS Plasma Priming Factor

LPS-Priming Cofactor	No. Studies	Priming Activity	Significance
		% of Simultaneously Conducted Heparinized Plasma Control	v Plasma	v HBSS
Plasma (heparin)^*	—	100	—	P < .0001
Plasma (CPD)	9	77.6 ± 13^†	NS	P < .001
Serum	7	71.1 ± 12	P < .05	P < .05
Cryoprecipitate	5	144.3 ± 17.5	P < .01	P < .001
HBSS	10	23.2 ± 5.8	P < .0001	—

LPS-Priming Cofactor	No. Studies	Priming Activity	Significance
		% of Simultaneously Conducted Heparinized Plasma Control	v Plasma	v HBSS
Plasma (heparin)^*	—	100	—	P < .0001
Plasma (CPD)	9	77.6 ± 13^†	NS	P < .001
Serum	7	71.1 ± 12	P < .05	P < .05
Cryoprecipitate	5	144.3 ± 17.5	P < .01	P < .001
HBSS	10	23.2 ± 5.8	P < .0001	—

Abbreviation: NS, not significant.

Anticoagulant used in preparing plasma is indicated in brackets.

Percent of simultaneously conducted LPS priming study with plasma (heparin) present as cofactor (mean ± SEM).